In recent years, the advent of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs), such as cetuximab and panitumumab, have contributed to improving the 5-year survival of CRC patients. This evidence concerns the gene EGFR and colorectal carcinoma.